Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQuadrise Regulatory News (QED)

Share Price Information for Quadrise (QED)

Share Price is delayed by 15 minutes
Get Live Data
1.995    -0.215 (-9.73%)
Bid:
1.905
Ask:
2.19
Spread: 0.285 (14.961%)
Market Cap: £40.02m
QED Live PriceLast checked at - London Stock Exchange

Intraday Quadrise Share Chart

Management Update

1 May 2025 07:00

RNS Number : 9240G
Quadrise PLC
01 May 2025
 

[Certain of the information contained within this announcement is deemed by the Company to constitute inside information as stipulated under The Market Abuse Regulation (EU 596/2014) pursuant to the Market Abuse (Amendment) (EU Exit) Regulations 2018. Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.]

 

 

1 May 2025

 

Quadrise plc

("Quadrise", "QED" or the "Company")

 

Management Update

 

Strengthening for Growth

 

Quadrise plc (AIM: QED), the energy transition technology company focused on the decarbonisation of shipping and heavy industry through deployment of low carbon fuels and biofuels, announces a planned reorganisation of its senior leadership team to support the Company as it scales up its commercial and technical activities, reflecting the accelerating momentum at Quadrise.

 

Jason Miles, Chief Executive Officer, will transition into a newly created role of Chief Technology Officer with effect from 1 June 2025. In this capacity, Jason will focus on accelerating the development and deployment of the Company's core technologies, including MSAR®, bioMSAR™ and bioMSAR™ Zero.

 

In particular, he will take full ownership of the ongoing commercial trials and associated technical programmes and partnerships which are of critical importance for the commercial evolution of the Company. Jason will continue to be a director on the board and will report to a new Chief Executive Officer, whom the Company has commenced a process to identify and appoint.

 

To enable Jason Miles to focus on his newly defined role, and to provide continuity and leadership ahead of the appointment of a new Chief Executive, Andy Morrison, Chairman of Quadrise, will take on additional executive duties on an interim basis with effect from 1 June 2025. Andy remains Chair of the board of directors.

 

In expanding the Board with a new CEO as an additional executive director, together with the CTO's enhanced focus on the deployment of the Company's technologies, the Board believes that leadership and execution capacity will be enhanced across the Company's major projects, enabling Quadrise to capture upcoming opportunities.

 

Further announcements regarding the CEO appointment process will be made, as appropriate, in due course.

 

Andy Morrison, Chair of Quadrise, commented:

 

"On behalf of the Board, I would like to thank Jason for his dedication to the Company. His deep technical insight and longstanding commitment to the Company's vision, together with his outstanding leadership skills, make him the ideal person to lead our technology and innovation at this pivotal stage. As we start to scale up, the appointment of a new Chief Executive Officer will enable us to strengthen our commercial capacity and executive bandwidth, ensuring we are positioned to capitalise on the growing opportunities in our target markets."

 

Jason Miles, Chief Executive Officer and Chief Technology Officer designate, added:

 

"This strategic realignment reflects the exciting new phase that Quadrise is entering, and I look forward to being able to focus even more closely on successfully delivering the industrial-scale client trials - critical steps towards commercialisation - and to driving our decarbonisation technology innovations and projects forward. I'm excited about the opportunities ahead and the role the Company will play in delivering sustainable, scalable energy solutions."

 

 

For further information please contact:

 

Quadrise Plc

+44 (0)20 7031 7321

Andy Morrison, Chairman

Jason Miles, Chief Executive Officer

 

 

Nominated Adviser

Cavendish Capital Markets Limited

 

 

+44 (0)20 7220 0500

Ben Jeynes

Katy Birkin

George Lawson

 

Joint Brokers

Shore Capital Stockbrokers Limited

 

 

+44 (0)20 7408 4090

Toby Gibbs (Corporate Advisory)

Fiona Conroy (Corporate Broking)

 

VSA Capital Limited

Andrew Raca (Corporate Finance)

Andrew Monk (Corporate Broking)

 

 

+44 (0)20 3005 5000

 

Public & Investor Relations

 

 

Tavistock Communications (Financial PR & IR)

Simon Hudson

Nick Elwes

Ruairi Millar

 

+44 (0) 20 7920 3150

 

 BLUE Communications Limited (Marine & Trade PR)

 Rhys Thomas

 Sam Deacon

 

 

 

+44 (0)7595 227750

+44 (0)7527 558846

 

 

 

About Quadrise

Quadrise is the supplier of MSAR® and bioMSAR™ emulsion technology, fuels and biofuels, providing innovative solutions to lower energy costs, pollution and greenhouse gas emissions today for the global power generation, shipping, industrial and oil industries.

Learn more at: www.quadrise.com

 

Follow us on social media:

LinkedIn: @Quadrise Plc

X: @QuadrisePlc

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEAKLEDSPSEFA
Date   Source Headline
1st Aug 20247:00 amRNSValkor Project Update
10th Jul 20247:00 amRNSMarine Project Update
26th Jun 20247:00 amRNSExtended agreement with BTG Bioliquids for bioMSAR
29th May 20247:00 amRNSRepresentation Agreement Addendum & Warrants Grant
28th May 20247:00 amRNSOCP Commercial Framework Agreement
2nd May 20247:00 amRNSQuadrise-Vertoro JDA to sea-trial bioMSAR Zero
29th Apr 20247:00 amRNSMarine Project Update
19th Apr 20247:00 amRNSValkor Project Update
12th Apr 20244:58 pmRNSResults of Open Offer
22nd Mar 20243:10 pmRNSExtension of Open Offer Closing Date
20th Mar 20241:01 pmRNSInvestor Presentation
19th Mar 20247:00 amRNSPlacing Results, Open Offer & Posting of Circular
18th Mar 20244:55 pmRNSProposed Placing, Subscription and Open Offer
18th Mar 20244:53 pmRNSInterim Results
15th Feb 20247:00 amRNSAgreement with Euthenia & BTG Bioliquids
6th Feb 20247:00 amRNSMarine Project Update
6th Dec 20237:00 amRNSUpdate re bioMSARâ„¢ and bioMSARâ„¢ Zero Development
27th Nov 20235:46 pmRNSResult of AGM
27th Nov 20237:00 amRNSAGM Statement
22nd Nov 20237:00 amRNSMorocco Project Update
9th Nov 20237:00 amRNSPublication of 2023 Sustainability Report
31st Oct 202312:45 pmRNSMorocco Project Update
27th Oct 20234:20 pmRNSPosting of Annual Report & Notice of AGM
24th Oct 20239:33 amRNSChange of Nominated Adviser
2nd Oct 20237:30 amRNSDirectorate Change
2nd Oct 20237:00 amRNSFinal Results and Notice of AGM
12th Sep 20237:00 amRNSMorocco Project Update
29th Aug 20237:00 amRNSValkor Project Update
24th Aug 202312:29 pmRNSValkor Update
18th Aug 20233:46 pmRNSMorocco Update
4th Aug 20237:00 amRNSIssue of Share Options and Director/PDMR Dealing
1st Aug 20234:15 pmRNSDirector/PDMR Shareholding
28th Jul 20234:25 pmRNSDirector/PDMR Shareholding
25th Jul 20233:34 pmRNSResults of Open Offer
7th Jul 202312:00 pmRNSInvestor Presentation
7th Jul 202310:38 amRNSPlacing Results, Open Offer & Posting of Circular
7th Jul 20237:00 amRNSProposed Placing and Open Offer
22nd Jun 20237:00 amRNSMorocco Update
12th Jun 20237:00 amRNSValkor Site License & Supply Agreement
8th Jun 20237:00 amRNSJoint Development Agreement with BTG Bioliquids
26th May 20237:00 amRNSVertoro Joint Development Agreement Update
22nd May 20237:00 amRNSMorocco Update
16th May 20234:29 pmRNSReplacement: Business Update
16th May 20237:00 amRNSBusiness Update
25th Apr 20237:00 amRNSAppointment of Joint Broker
29th Mar 20237:00 amRNSInterim Results
28th Mar 20237:00 amRNSChange of Company Name
22nd Oct 20155:26 pmRNSDelisting of Quintain ordinary shares
15th Oct 20154:30 pmRNSHolding(s) in Company
15th Oct 20154:30 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.